A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D [ON/OFF] Inhibitor, as Monotherapy and with Cetuximab, in Patients with Metastatic KRAS G12D-Mutated Pancreatic Cancer [TARGET-D 201] (NCT07644559)
VS-7375-201
This trial is Currently recruiting
Registration number NCT07644559
Program & service
This trial is being run with the Cancer service, and as part of the Medical Oncology program.
Trial phase
Phase 2
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Ben Markman
Key inclusion data
• Histopathology confirmed PDAC; • Measurable disease per RECIST 1.1; • Local testing confirmed KRAS G12D mutation with no documented co-existing common RAS mutation(s); • ECOG PS=0 or 1; • Adequate organ function.More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.